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CTO intervention objectively can be more frequently associated acute exacerbation of
CRI or new onset acute renal insufficiency. There have been limited data regarding the
impact of chronic renal insufficiency on major angiographic and clinical outcomes
following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for
CTO lesions.
Methods: A total 234 consecutive patients with CTO lesion were underwent PCI with
DESs between 2004 and 2010. We compared clinical outcomes of 22 patients with CRI
with 212 patients without CRI for at least up to 6 months. Further, we investigated
whether there are differences between CTO patients with CRI and non-CTO patients
with CRI. All CRI patients were managed with enough prehydration and
N-acetylcysteine administration.
Results: There were no significant differences between the two groups. At 6 months,
major clinical outcomes including cardiac mortality and Q-wave myocardial infarction
(MI) were higher in the CRI group. Further, there was a trend toward higher incidence
of target lesion revascularization (TLR)-major adverse cardiac events (MACES) in the
CRI group (Table).
Conclusions: Patients with CTO lesion and combined CRI at baseline showed worse
mid-term clinical outcomes as compared with those without CRI following successful
CTO PCI with DESs. Updated data will be presented at the time of presentation.
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Background: Chronic total occlusion (CTO) intervention is still challenging because of
the limited procedural success rate and higher recurrence. It is not clear whether the
angiographic and clinical outcomes may different between patients (pts) with single vessel
CTO (SV-CTO) and multi-vessel CTO (MV-CTO).
Methods: A total of 238 consecutive pts underwent CTO intervention were divided
according to the number of target CTO vessels (SV-CTO: n220 pts, MV-CTO: n18
pts). Six-month angiographic and 24-month clinical outcomes were compared between
the two groups.
Results: The baseline clinical characteristics were balanced between the two groups
except that incidence of myocardial infarction (MI, 61.1 vs. 23.6%, p0.001) and a lower
left ventricular ejection fraction% (LVEF%, 42.0  11.80 vs. 50.28  11.15 p 0.003)
was higher in the MV-CTO group. The overall procedural success rate was a lower in the
MV-CTO group (77.7% vs. 94.0 % p0.009). Procedural characteristics and procedure
related complications including perforation and dissection were not different between the
two groups. Once the CTO was successfully treated, the anngiographic outcomes at 6
months and major clinical outcomes up to 24 months were similar between the two
groups (Table).
Conclusions: Baseline characteristics were worse and the procedural success rate was
lower in the MV-CTO group. However, once the CTO lesion was successfully
recanalyzed, the safety profiles, complications, mid-term angiographic and clinical
outcomes up to 24 months were similar between the two groups.
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Background: IMPELLA® is a new vascular micro-axial blood pump with a flow of 2.5
L/min. It allows the unloading of the left ventricle.
Methods: 11 consecutive male patients (mean age 657 years), with coronary artery
disease (9 with three vessels disease, 2 with left main stenosis and two coronary vessels
disease, 5 of them with last remaining vessel) and severe left ventricular dysfunction (mean
EF 244%) were enrolled. All were poor surgical candidates because of severe co-
morbidities: diabetes 63%, renal insufficiency on dialysis 27%, severe respiratory insuffi-
ciency 18%. Coronary artery lesions were 70% type C and 30% type B2. All these patients
underwent high-risk PCI with Impella support. Cardiac index (CI), pulmonary wedge
pressure (PWP and derived parameters were monitored by Swan-Ganz Catheter, while
LVEF was measured from TEE.
Results: Success rate was 100% without any device-related adverse event. The average
time of IMPELLA® support was 4216 min. No pts needed pharmacologic inotropic
support. During IMPELLA® there was a significant improvement of CI (from 2.150,8
l/min/sm to 2.830,3 l/min/sm, p0.01), stroke volume (from 37.215 ml to 49.611
ml, p 0.01), mean blood pressure from 558 mmHg to 647 mmHg (p 0.001) while
PWP pulmonary vascular resistances significantly decreased (from 24.8mmHg11 to
20.76 mmHg, and 723146 dyne/sec/cm-5 to 62093 dyne/sec/cm-5, p0.01).
Mean coronary occlusion time during IMPELLA® support was 18418 sec.
During the procedures LV ejection fraction, stroke volume, CI, PWP, mean blood
pressure and pulmonary vascular resistance did not show any significant changes.
Conclusion: Left Ventricle Unloading with Impella during complex PCI in pts with
severe left ventricular dysfunction is able to improve hemodynamic basal condition, and to
maintain it during prolonged coronary occlusion.
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Background: In this study we compare the outcomes of the paclitaxel-eluting stent
(PES) versus the everolimus-eluting stent (EES) treated patients at a tertiary medical
center and up to two years follow up.
Methods: Unselected consecutive patients were retrospectively recruited following
stenting with PES (159 patients) or EES (189 patients). The first 100 consecutive patients
in each cohort underwent syntax scoring. The primary endpoint of the study was target
lesion failure (TLF) defined as the combined endpoint of cardiac death, non fatal myocardial
infarction or target lesion revascularization (TLR). Secondary endpoints included target vessel
revascularization (TVR), target lesion revascularization (TLR), target vessel failure (TVF),
acute stent thrombosis (ST), total death, cardiac death, and non fatal myocardial infarction
(MI). Analysis was performed with patient number as the denominator.
Results: The syntax scores in the 2 groups were similar (20.3  13.9 vs 20.4  13.8,
p0.97). Patients treated with the PES stent had less congestive heart failure and
restenotic lesions, but a higher prevalence of longer lesions, non left main bifurcations, and
required more stents per patient (4.3  2.8 vs. 2.9  2.1). The primary unadjusted
outcome of TLF occurred in 29.3% PES vs 20.3% EES (p0.059). The secondary
unadjusted endpoints for PES vs EES respectively were: TVF 36.7% vs 28.0% (p0.106),
TVR 35.7% vs 26.5% (p0.079), definite and probable ST 1.2% vs 1.6%, non fatal MI
4.5% vs. 4.2%, and cardiac mortality 5.6% vs 3.2%. A propensity matched analysis showed
no significant difference in the primary endpoint of TLF (28.6%  16 vs 24.6%  14,
p0.67) in PES vs EES respectively.
Conclusion: Using unadjusted analysis, EES had lower TLF than PES in a broad cohort
of patients and lesions undergoing PCI. However, when baseline differences between the
2 cohorts were adjusted for, similar efficacy between the PES and EES was seen at 2 years
follow-up.
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Background: Small vessel diameter is associated with increased restenosis rates and
adverse outcomes following coronary stenting. The PLATINUM Japan Small Vessel
multicenter study specifically assessed small vessel stenting in Japanese patients treated
with the PROMUS Element everolimus-eluting stent (Boston Scientific, Natick, MA).
Follow-up beyond 1 year has not been reported previously.
Methods: Patients with a single de novo target lesion28 mm long and2.25 to2.50
mm in diameter were eligible for treatment with a 2.25 mm diameter PROMUS Element
stent.
Results: A total of 60 patients were enrolled at 14 clinical sites; 32 patients were
randomized to receive routine angiography following the 1-year clinical follow-up
(angiography was completed in 29 patients). Patients were 69.29.8 years of age, 68.3%
male, and 36.7% had medically treated diabetes. Average baseline reference vessel
diameter was 2.020.26 mm. Technical success and procedural success were both 100%
(60/60). Post-dilation was used in 70.0% with a 16.6 atm average pressure. Dual
antiplatelet treatment was used in 78.3% of patients at 2 years post-procedure. Two-year
clinical follow-up is complete in 100% of patients. Through 365 days post-procedure,
there were no major adverse cardiac events. In-stent late loss was 0.180.30 mm in the
angiographic subset. Following angiographic assessments (366-396 days post-procedure)
target lesion revascularization (TLR) occurred in 2 patients (including 1 patient in the
angiographic subset); there were no additional TLRs through the 2-year follow-up.
Target vessel revascularization outside the target lesion occurred in 3 patients through the
2-year follow-up. One patient (1.7%) experienced a non-Q-wave myocardial infarction
(MI) in the target vessel 413 days post-procedure. There were no Q-wave MIs or stent
thromboses through 2 years.
Conclusion: The results support the safety and efficacy of the PROMUS Element 2.25
mm stent in Japanese patients.
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Drug Eluting Balloon for De-Novo, In stent Restenosis and Bifurcation Lesions of
Coronary Artery Disease: Short and Intermediate Results, Prospective Registry
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Objectives: This prospective study designed to assess the safety and short and
intermediate term efficacy of drug eluting balloon (DEB) in the treatment of de-novo,
in-stent restenosis and bifurcation coronary artery disease (CAD) in Saudi Arabic
Population.
Methods: Total of 64 patients so far enrolled in a prospective registry using a Be Brown
Paclitaxel-coated balloon (DEB) at our hospital, 61 patients were studied for short and
intermediate term outcomes (6 to 12 months). All patients with symptomatic CAD
requiring percutaneous intervention (PCI) with DEB were included. Clinical follow-up
was conducted at 6 to 12 months. Coronary angiography (CAG) or SPECT Scan were
done in 70% of patients during this period. Primary outcome was a composite of target
vessel revascularization and mortality.
Results: Procedural success was achieved in 96% of the patients. Two patients were
failed due to failed DEB to cross heavily calcified vessel. Mean age was 60.830 years. 47
patients (77%) presented with stable angina and 9 patients 15% with acute coronary
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